Evidence map›Paper›PMID 39541411›Full record

ArticlePLoS computational biology2024

GeM-LR: Discovering predictive biomarkers for small datasets in vaccine studies.

Lin Lin, Rachel L Spreng, Kelly E Seaton, S Moses Dennison, Lindsay C Dahora, Daniel J Schuster, Sheetal Sawant, Peter B Gilbert, Youyi Fong, Neville Kisalu and 3 more

Abstract read
In one paragraph

Article in PLoS computational biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lin LinDepartment of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, United States of America.ORCID 0000-0002-7464-1172
Rachel L SprengCenter for Human Systems Immunology, Duke University, Durham, North Carolina, United States of America.
Kelly E SeatonCenter for Human Systems Immunology, Duke University, Durham, North Carolina, United States of America.ORCID 0000-0002-2009-3270
S Moses DennisonCenter for Human Systems Immunology, Duke University, Durham, North Carolina, United States of America.
Lindsay C DahoraCenter for Human Systems Immunology, Duke University, Durham, North Carolina, United States of America.
Daniel J SchusterCenter for Human Systems Immunology, Duke University, Durham, North Carolina, United States of America.
Sheetal SawantCenter for Human Systems Immunology, Duke University, Durham, North Carolina, United States of America.
Peter B GilbertVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Youyi FongVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Neville KisaluCenter for Vaccine Innovation and Access, PATH, Washington, DC, United States of America.
Andrew J PollardOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
Georgia D TomarasCenter for Human Systems Immunology, Duke University, Durham, North Carolina, United States of America.
Jia LiDepartment of Statistics, The Pennsylvania State University, Pennsylvania, United States of America.

Funding

SDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9M
Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5M
Structure-Function Analytics CoreP01AI162242 · NIAID · DUKE UNIVERSITY · PI TOMARAS, GEORGIA DORIS · 2021 to 2025
$22.2M
Stimulating Access to Research in Residency (StARR) - NIAIDR38AI140297 · NIAID · DUKE UNIVERSITY · PI Rachel G Greenberg, David H. Harpole · 2018 to 2026
$2.4M
NIAID NIH HHS P01 AI162242NIAID NIH HHS P30 AI064518NIAID NIH HHS R38 AI140297NIAID NIH HHS UM1 AI068635
6 · The paper itself

Abstract

Despite significant progress in vaccine research, the level of protection provided by vaccination can vary significantly across individuals. As a result, understanding immunologic variation across individuals in response to vaccination is important for developing next-generation efficacious vaccines. Accurate outcome prediction and identification of predictive biomarkers would represent a significant step towards this goal. Moreover, in early phase vaccine clinical trials, small datasets are prevalent, raising the need and challenge of building a robust and explainable prediction model that can reveal heterogeneity in small datasets. We propose a new model named Generative Mixture of Logistic Regression (GeM-LR), which combines characteristics of both a generative and a discriminative model. In addition, we propose a set of model selection strategies to enhance the robustness and interpretability of the model. GeM-LR extends a linear classifier to a non-linear classifier without losing interpretability and empowers the notion of predictive clustering for characterizing data heterogeneity in connection with the outcome variable. We demonstrate the strengths and utility of GeM-LR by applying it to data from several studies. GeM-LR achieves better prediction results than other popular methods while providing interpretations at different levels.

Indexed as

BiomarkersComputational BiologyVaccinesAlgorithmsHumansLogistic ModelsVaccinationBiomarkersVaccines

Identifiers

PMID39541411
PMCPMC11594404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.